ATE550648T1 - Adamts4 als blut-biomarker und therapeutisches ziel bei chronischem nierenversagen - Google Patents

Adamts4 als blut-biomarker und therapeutisches ziel bei chronischem nierenversagen

Info

Publication number
ATE550648T1
ATE550648T1 AT08768680T AT08768680T ATE550648T1 AT E550648 T1 ATE550648 T1 AT E550648T1 AT 08768680 T AT08768680 T AT 08768680T AT 08768680 T AT08768680 T AT 08768680T AT E550648 T1 ATE550648 T1 AT E550648T1
Authority
AT
Austria
Prior art keywords
therapeutic target
blood biomarker
adamts4
chronic kidney
kidney failure
Prior art date
Application number
AT08768680T
Other languages
English (en)
Inventor
Slobodan Vukicevic
Lovorka Grgurevic
Original Assignee
Genera Istrazivanja D O O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genera Istrazivanja D O O filed Critical Genera Istrazivanja D O O
Application granted granted Critical
Publication of ATE550648T1 publication Critical patent/ATE550648T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96419—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT08768680T 2007-06-22 2008-06-20 Adamts4 als blut-biomarker und therapeutisches ziel bei chronischem nierenversagen ATE550648T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93685007P 2007-06-22 2007-06-22
PCT/US2008/007713 WO2009002451A2 (en) 2007-06-22 2008-06-20 Adamts4 as a blood biomarker and therapeutic target for chronis renal failure

Publications (1)

Publication Number Publication Date
ATE550648T1 true ATE550648T1 (de) 2012-04-15

Family

ID=40186208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08768680T ATE550648T1 (de) 2007-06-22 2008-06-20 Adamts4 als blut-biomarker und therapeutisches ziel bei chronischem nierenversagen

Country Status (4)

Country Link
US (1) US8263072B2 (de)
EP (2) EP2455755A3 (de)
AT (1) ATE550648T1 (de)
WO (1) WO2009002451A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3078664T (pt) 2009-12-17 2019-05-31 Boehringer Ingelheim Animal Health Usa Inc Composições antiparasitárias de di-hidroazoles
HUE042360T2 (hu) 2011-09-12 2019-06-28 Merial Inc Izoxazolin hatóanyagot tartalmazó parazitaellenes készítmények, ezek elõállítása és alkalmazása
WO2013109829A1 (en) * 2012-01-20 2013-07-25 Glaxosmithkline Intellectual Property Development Ltd Anti-adamts4 antibodies and methods of treatment
AP2014007874A0 (en) 2012-02-06 2014-08-31 Merial Ltd Parasiticidal oral veterinary compositions comprising systemetically- acting active agents, methods and uses thereof
WO2015066277A1 (en) 2013-11-01 2015-05-07 Merial Limited Antiparisitic and pesticidal isoxazoline compounds
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
ES2950426T3 (es) 2015-08-12 2023-10-09 Univ Columbia Procedimientos de tratamiento de la depleción de volumen y la lesión renal
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2021050089A1 (en) * 2019-09-09 2021-03-18 Washington State University Genetic test for identifying cats at a high risk for developing tubulointerstitial fibrosis
WO2021242481A1 (en) 2020-05-28 2021-12-02 Boehringer Ingelheim Animal Health USA Inc. Bi-modal release intra-ruminal capsule device and methods of use thereof
WO2022133420A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
EP4262789A1 (de) 2020-12-21 2023-10-25 Boehringer Ingelheim Vetmedica GmbH Parasitizide manschette mit isoxazolinverbindungen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2228742A1 (en) * 1997-04-30 1998-10-30 Smithkline Beecham Corporation Crfg-1, a target and marker for chronic renal failure
WO2000053774A2 (en) 1999-03-08 2000-09-14 Neurocrine Biosciences, Inc. Metalloproteinases and methods of use therefor
US6448388B1 (en) * 2000-08-16 2002-09-10 Lexicon Genetics Incorporated Human proteases and polynucleotides encoding the same
EP1136547A3 (de) * 2000-03-22 2002-09-25 Pfizer Products Inc. Adamts Polypeptide, Nucleinsäuren die dafür kodieren und deren Verwendungen
WO2002051998A1 (fr) * 2000-12-25 2002-07-04 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle protease
JP3689103B2 (ja) * 2002-06-20 2005-08-31 アステラス製薬株式会社 新規プロモーター
CN1681920A (zh) * 2002-07-29 2005-10-12 惠氏公司 修饰的admts4分子及其使用方法
US20100062431A1 (en) * 2006-05-18 2010-03-11 Sanofi-Aventis Use of adamts4 gene and protein polymorphisms
EP2049893B1 (de) 2006-07-21 2016-11-30 GENERA ISTRAZIVANJA d.o.o. Anti-BMP-1-1 und anti-BMP-1-3 Antikörper zur Behandlung von chronischer Niereninsuffizienz

Also Published As

Publication number Publication date
WO2009002451A2 (en) 2008-12-31
EP2171450A2 (de) 2010-04-07
EP2171450A4 (de) 2010-07-21
WO2009002451A3 (en) 2009-12-30
US8263072B2 (en) 2012-09-11
EP2455755A3 (de) 2012-08-15
US20100254997A1 (en) 2010-10-07
EP2455755A2 (de) 2012-05-23
EP2171450B1 (de) 2012-03-21

Similar Documents

Publication Publication Date Title
EP2171450A4 (de) Adamts4 als blut-biomarker und therapeutisches ziel bei chronischem nierenversagen
BRPI0811411A2 (pt) "kit de tratamento de um conduto de circulação do sangue"
IL262236B (en) Systems and methods for ex vivo organ care
EP2225396A4 (de) Mikro-rna-expressionsprofilerstellung und abzielen darauf in peripherem blut bei lungenkrebs
EA200802213A1 (ru) Способы лечения заболеваний крови
CY2018026I2 (el) Χρηση στρωματικων βλαστοκυτταρων λαμβανομενων απο λιπωδη ιστο στην θεραπεια συριγγιου
WO2010091049A3 (en) Diagnosis and treatment of cancer
CY2016015I1 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
EP1809175A4 (de) Objektive bestimmung von chronischen schmerzen bei patienten
EP1885281A4 (de) Stentvorrichtungen zur behandlung über körperlumen und verwendungsverfahren
EA201300213A1 (ru) Применение ингибиторов dpp iv
EP1755584A4 (de) Behandlung von myopie
EP2262519A4 (de) Behandlung von gehör- und gleichgewichtsstörungen mit redoxaktiven therapeutika
DK2024367T3 (da) Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
EP1863558A4 (de) Elektrochirurgische kanüle
EP1887543A4 (de) Katheter-chirurgiesimulation
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
CL2008002368A1 (es) Uso de gaboxadol para preparar un medicamento util en el tratamiento de la depresion en pacientes que tienen uno o mas marcadores inflamatorios elevados o anormales.
IN2014MN01227A (de)
DE602005006990D1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
EP1982660A4 (de) Behandlungsendoskop
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
EP1984017A4 (de) Verfahren zur therapie oder prophylaxe von durch erhöhte durchblutung verursachten gewebeschäden